NEMA NU 4-2008 comparison of preclinical PET imaging systems

A finely segmented semi-monolithic detector tailored for high-resolution PET

BACKGROUND

Preclinical research and organ-dedicated applications use and require high (spatial-)resolution positron emission tomography (PET) detectors to visualize small structures (early) and understand biological processes at a finer level of detail. Researchers seeking to improve detector and image spatial resolution have explored various detector designs. Current commercial high-resolution systems often employ finely pixelated or monolithic scintillators, each with its limitations.

PURPOSE

We present a semi-monolithic detector, tailored for high-resolution PET applications with a spatial resolution in the range of 1 mm or better, merging concepts of monolithic and pixelated crystals. The detector features LYSO slabs measuring (24 × 10 × 1) mm3, coupled to a 12 × 12 readout channel photosensor with 4 mm pitch. The slabs are grouped in two arrays of 44 slabs each to achieve a higher optical photon density despite the fine segmentation.

METHODS

We employ a fan beam collimator for fast calibration to train machine-learning-based positioning models for all three dimensions, including slab identification and depth-of-interaction (DOI), utilizing gradient tree boosting (GTB). The data for all dimensions was acquired in less than 2 h. Energy calculation was based on a position-dependent energy calibration. Using an analytical timing calibration, time skews were corrected for coincidence timing resolution (CTR) estimation.

RESULTS

Leveraging machine-learning-based calibration in all three dimensions, we achieved high detector spatial resolution: down to 1.18 mm full width at half maximum (FWHM) detector spatial resolution and 0.75 mm mean absolute error (MAE) in the planar-monolithic direction, and 2.14 mm FWHM and 1.03 mm MAE for DOI at an energy window of (435-585) keV. Correct slab interaction identification in planar-segmented direction exceeded 80%, alongside an energy resolution of 12.7% and a CTR of 450 ps FWHM.

CONCLUSIONS

The introduced finely segmented, high-resolution slab detector demonstrates appealing performance characteristics suitable for high-resolution PET applications. The current benchtop-based detector calibration routine allows these detectors to be used in PET systems.

Efficient image reconstruction for a small animal PET system with dual-layer-offset detector design

BACKGROUND

A compact PET/SPECT/CT system Inliview-3000B has been developed to provide multi-modality information on small animals for biomedical research. Its PET subsystem employed a dual-layer-offset detector design for depth-of-interaction capability and higher detection efficiency, but the irregular design caused some difficulties in calculating the normalization factors and the sensitivity map. Besides, the relatively larger (2 mm) crystal cross-section size also posed a challenge to high-resolution image reconstruction.

PURPOSE

We present an efficient image reconstruction method to achieve high imaging performance for the PET subsystem of Inliview-3000B.

METHODS

List mode reconstruction with efficient system modeling was used for the PET imaging. We adopt an on-the-fly multi-ray tracing method with random crystal sampling to model the solid angle, crystal penetration and object attenuation effect, and modify the system response model during each iteration to improve the reconstruction performance and computational efficiency. We estimate crystal efficiency with a novel iterative approach that combines measured cylinder phantom data with simulated line-of-response (LOR)-based factors for normalization correction before reconstruction. Since it is necessary to calculate normalization factors and the sensitivity map, we stack the two crystal layers together and extend the conventional data organization method here to index all useful LORs. Simulations and experiments were performed to demonstrate the feasibility and advantage of the proposed method.

RESULTS

Simulation results showed that the iterative algorithm for crystal efficiency estimation could achieve good accuracy. NEMA image quality phantom studies have demonstrated the superiority of random sampling, which is able to achieve good imaging performance with much less computation than traditional uniform sampling. In the spatial resolution evaluation based on the mini-Derenzo phantom, 1.1 mm hot rods could be identified with the proposed reconstruction method. Reconstruction of double mice and a rat showed good spatial resolution and a high signal-to-noise ratio, and organs with higher uptake could be recognized well.

CONCLUSION

The results validated the superiority of introducing randomness into reconstruction, and demonstrated its reliability for high-performance imaging. The Inliview-3000B PET subsystem with the proposed image reconstruction can provide rich and detailed information on small animals for preclinical research.

PET/SPECT/spectral-CT/CBCT imaging in a small-animal radiation therapy platform: A Monte Carlo study-Part I: Quad-modal imaging

BACKGROUND

In spite of the tremendous potential of game-changing biological image- and/or biologically guided radiation therapy (RT) and adaptive radiation therapy for cancer treatment, existing limited strategies for integrating molecular imaging and/or biological information with RT have impeded the translation of preclinical research findings to clinical applications. Additionally, there is an urgent need for a highly integrated small-animal radiation therapy (SART) platform that can seamlessly combine therapeutic and diagnostic capabilities to comprehensively enhance RT for cancer treatment.

PURPOSE

We investigated a highly integrated quad-modal on-board imaging configuration combining positron emission tomography (PET), single-photon emission computed tomography (SPECT), photon-counting spectral CT, and cone-beam computed tomography (CBCT) in a SART platform using a Monte Carlo model as a proof-of-concept.

METHODS

The quad-modal on-board imaging configuration of the SART platform was designed and evaluated by using the GATE Monte Carlo code. A partial-ring on-board PET imaging subsystem, utilizing advanced semiconductor thallium bromide detector technology, was designed to achieve high sensitivity and spatial resolution. On-board SPECT, photon-counting spectral-CT, and CBCT imaging were performed using a single cadmium zinc telluride flat detector panel. The absolute peak sensitivity and scatter fraction of the PET subsystem were estimated by using simulated phantoms described in the NEMA NU-4 standard. The spatial resolution of the PET image of the platform was evaluated by imaging a simulated micro-Derenzo hot-rod phantom. To evaluate the quantitative imaging capability of the system's spectral CT, the Bayesian eigentissue decomposition (ETD) method was utilized to quantitatively decompose the virtual noncontrast (VNC) electron densities and iodine contrast agent fractions in the Kidney1 inserts mixed with the iodine contrast agent within the simulated phantoms. The performance of the proposed quad-model imaging in the platform was validated by imaging a simulated phantom with multiple imaging probes, including an iodine contrast agent and radioisotopes of 18F and 99mTc.

RESULTS

The PET subsystem demonstrated an absolute peak sensitivity of 18.5% at the scanner center, with an energy window of 175-560 KeV, and a scatter fraction of only 3.5% for the mouse phantom, with a default energy window of 480-540 KeV. The spatial resolution of PET on-board imaging exceeded 1.2 mm. All imaging probes were identified clearly within the phantom. The PET and SPECT images agreed well with the actual spatial distributions of the tracers within the phantom. Average relative errors on electron density and iodine contrast agent fraction in the Kidney1 inserts were less than 3%. High-quality PET images, SPECT images, spectral-CT images (including iodine contrast agent fraction images and VNC electron density images), and CBCT images of the simulated phantom demonstrated the comprehensive multimodal imaging capability of the system.

CONCLUSIONS

The results demonstrated the feasibility of the proposed quad-modal imaging configuration in a SART platform. The design incorporates anatomical, molecular, and functional information about tumors, thereby facilitating successful translation of preclinical studies into clinical practices.

Crystal scatter effects in a large-area dual-panel Positron Emission Mammography system

Positron Emission Mammography (PEM) is a valuable molecular imaging technique for breast studies using pharmaceuticals labeled with positron emitters and dual-panel detectors. PEM scanners normally use large scintillation crystals coupled to sensitive photodetectors. Multiple interactions of the 511 keV annihilation photons in the crystals can result in event mispositioning leading to a negative impact in radiopharmaceutical uptake quantification. In this work, we report the study of crystal scatter effects of a large-area dual-panel PEM system designed with either monolithic or pixelated lutetium yttrium orthosilicate (LYSO) crystals using the Monte Carlo simulation platform GATE. The results show that only a relatively small fraction of coincidences (~20%) arise from events where both coincidence photons undergo single interactions (mostly through photoelectric absorption) in the crystals. Most of the coincidences are events where at least one of the annihilation photons undergoes a chain of Compton scatterings: approximately 79% end up in photoelectric absorption while the rest (<1%) escape the detector. Mean positioning errors, calculated as the distance between first hit and energy weighted (assigned) positions of interaction, were 1.70 mm and 1.92 mm for the monolithic and pixelated crystals, respectively. Reconstructed spatial resolution quantification with a miniDerenzo phantom and a list mode iterative reconstruction algorithm shows that, for both crystal types, 2 mm diameter hot rods were resolved, indicating a relatively small effect in spatial resolution. A drastic reduction in peak-to-valley ratios for the same hot-rod diameters was observed, up to a factor of 14 for the monolithic crystals and 7.5 for the pixelated ones.

MCGPU-PET: An Open-Source Real-Time Monte Carlo PET Simulator

Monte Carlo (MC) simulations are commonly used to model the emission, transmission, and/or detection of radiation in Positron Emission Tomography (PET). In this work, we introduce a new open-source MC software for PET simulation, MCGPU-PET, which has been designed to fully exploit the computing capabilities of modern GPUs to simulate the acquisition of more than 100 million coincidences per second from voxelized sources and material distributions. The new simulator is an extension of the PENELOPE-based MCGPU code previously used in cone-beam CT and mammography applications. We validated the accuracy of the accelerated code by comparing it to GATE and PeneloPET simulations achieving an agreement within 10 percent approximately. As an example application of the code for fast estimation of PET coincidences, a scan of the NEMA IQ phantom was simulated. A fully 3D sinogram with 6382 million true coincidences and 731 million scatter coincidences was generated in 54 seconds in one GPU. MCGPU-PET provides an estimation of true and scatter coincidences and spurious background (for positron-gamma emitters such as 124I) at a rate 3 orders of magnitude faster than CPU-based MC simulators. This significant speed-up enables the use of the code for accurate scatter and prompt-gamma background estimations within an iterative image reconstruction process.

Identification of (R)-[18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development

This study aimed to evaluate (R)-[18F]YH134 as a novel PET tracer for imaging monoacylglycerol lipase (MAGL). Considering the ubiquitous expression of MAGL throughout the whole body, the impact of various MAGL inhibitors on (R)-[18F]YH134 brain uptake and its application in brain-periphery crosstalk were explored. Methods: MAGL knockout and wild-type mice were used to evaluate (R)-[18F]YH134 in in vitro autoradiography and PET experiments. To explore the impact of peripheral MAGL occupancy on (R)-[18F]YH134 brain uptake, PET kinetics with an arterial input function were studied in male Wistar rats under baseline and blocking conditions. Results: In in vitro autoradiography, (R)-[18F]YH134 revealed a heterogeneous distribution pattern with high binding to MAGL-rich brain regions in wild-type mouse brain slices, whereas the radioactive signal was negligible in MAGL knockout mouse brain slices. The in vivo brain PET images of (R)-[18F]YH134 in wild-type and MAGL knockout mice demonstrated its high specificity and selectivity in mouse brain. A Logan plot with plasma input function was applied to estimate the distribution volume (V T) of (R)-[18F]YH134. V T was significantly reduced by a brain-penetrant MAGL inhibitor but was unchanged by a peripherally restricted MAGL inhibitor. The MAGL target occupancy in the periphery was estimated using (R)-[18F]YH134 PET imaging data from the brain. Conclusion: (R)-[18F]YH134 is a highly specific and selective PET tracer with favorable kinetic properties for imaging MAGL in rodent brain. Our results showed that blocking of the peripheral target influences brain uptake but not the V T of (R)-[18F]YH134. (R)-[18F]YH134 can be used for estimating the dose of MAGL inhibitor at half-maximal peripheral target occupancy.

Effect of depth of interaction resolution on the spatial resolution of SIAT aPET

Objective.Spatial resolution is a crucial parameter for a positron emission tomography (PET) scanner. The spatial resolution of a high-resolution small animal PET scanner is significantly influenced by the effect of depth of interaction (DOI) uncertainty. The aim of this work is to investigate the impact of DOI resolution on the spatial resolution of a small animal PET scanner called SIAT aPET and determine the required DOI resolution to achieve nearly uniform spatial resolution within the field of view (FOV).Approach. The SIAT aPET detectors utilize 1.0 × 1.0 × 20 mm3crystals, with an average DOI resolution of ∼2 mm. A default number of 16 DOI bins are used during data acquisition. First, a Na-22 point source was scanned in the center of the axial FOV with different radial offsets. Then, a Derenzo phantom was scanned at radial offsets of 0 and 15 mm in the center axial FOV. The measured DOI information was rebinned to 1, 2, 4 and 8 DOI bins to mimic different DOI resolutions of the detectors during image reconstruction.Main results. Significant artifacts were observed in images obtained from both the point source and Derenzo phantom when using only one DOI bin. When accurate measurement of DOI is not achieved, degradation in spatial resolution is more pronounced in the radial direction compared to tangential and axial directions for large radial offsets. The radial spatial resolutions at a 30 mm radial offset are 5.05, 2.62, 1.24, 0.86 and 0.78 mm when using 1, 2, 4, 8, or 16 DOI bins, respectively. The axial spatial resolution improved from ∼1.3 to 0.7 mm as the number of DOI bins increased from 1 to 16 at radial offsets from 0 to 25 mm. Two DOI bins are required to obtain images without significant artifacts. The required DOI resolution is about three times the crystal width of SIAT aPET to achieve a uniform submillimeter spatial resolution within the central 60 mm FOV and resolve the 1 mm rods of the Derenzo phantom at both positions.

PET imaging and quantification of small animals using a clinical SiPM-based camera

BACKGROUND

Small-animal PET imaging is an important tool in preclinical oncology. This study evaluated the ability of a clinical SiPM-PET camera to image several rats simultaneously and to perform quantification data analysis.

METHODS

Intrinsic spatial resolution was measured using 18F line sources, and image quality was assessed using a NEMA NU 4-2018 phantom. Quantification was evaluated using a fillable micro-hollow sphere phantom containing 4 spheres of different sizes (ranging from 3.95 to 7.86 mm). Recovery coefficients were computed for the maximum (Amax) and the mean (A50) pixel values measured on a 50% isocontour drawn on each sphere. Measurements were performed first with the phantom placed in the centre of the field of view and then in the off-centre position with the presence of three scattering sources to simulate the acquisition of four animals simultaneously. Quantification accuracy was finally validated using four 3D-printed phantoms mimicking rats with four subcutaneous tumours each. All experiments were performed for both 18F and 68Ga radionuclides.

RESULTS

Radial spatial resolutions measured using the PSF reconstruction algorithm were 1.80 mm and 1.78 mm for centred and off-centred acquisitions, respectively. Spill-overs in air and water and uniformity computed with the NEMA phantom centred in the FOV were 0.05, 0.1 and 5.55% for 18F and 0.08, 0.12 and 2.81% for 68Ga, respectively. Recovery coefficients calculated with the 18F-filled micro-hollow sphere phantom for each sphere varied from 0.51 to 1.43 for Amax and from 0.40 to 1.01 for A50. These values decreased from 0.28 to 0.92 for Amax and from 0.22 to 0.66 for A50 for 68 Ga acquisition. The results were not significantly different when imaging phantoms in the off-centre position with 3 scattering sources. Measurements performed with the four 3D-printed phantoms showed a good correlation between theoretical and measured activity in simulated tumours, with r2 values of 0.99 and 0.97 obtained for 18F and 68Ga, respectively.

CONCLUSION

We found that the clinical SiPM-based PET system was close to that obtained with a dedicated small-animal PET device. This study showed the ability of such a system to image four rats simultaneously and to perform quantification analysis for radionuclides commonly used in oncology.

A New Method for Optimizing the Size of Axial FOV in TOF-PEM to Improve Performance of the Scanner

Background

Positron Emission Mammography (PEM) is a nuclear medicine imaging tool, playing a significant role in the diagnosis of patients with breast cancer. These days, many research has been done in order to improve the performance of this system.

Objective

This study aims to propose a new method for optimizing the size of axial Field of View (FOV) in PEMs and improving the performance of the systems.

Material and Methods

In this analytical study, a conventional Inveon PET is simulated using GATE in order to validate the simulation. For this simulation, the mean relative difference is 2.91%, showing the precision and correction of simulation and consequently it is benchmarked. In the next step, for design of the new optimized detector, several validated simulations are performed in order to find the best geometry.

Results

The best result is obtained with the axial FOV of 101.7 mm. It has 1.6×1.6×15 mm3 lutetium yttrium orthosilicate (LYSO) crystals. The detector consists of 6 block rings with 30 detector blocks in each ring. In this paper, the performance of the scanner is improved and the geometry is optimized. Sensitivity and scatter fraction of the designed scanner are 4.65% and 21.2%, respectively, also noise equivalent count rate (NECR) is 105.442 kcps.

Conclusion

The results showed 1 up to 3% improvement in the sensitivity of this new detector compared with different PEMs.

Comparison of three 18F-labeled 2-nitroimidazoles for imaging hypoxia in breast cancer xenografts: [18F]FBNA, [18F]FAZA and [18F]FMISO

BACKGROUND

Tumour hypoxia is associated with increased metastasis, invasion, poor therapy response and prognosis. Most PET radiotracers developed and used for clinical hypoxia imaging belong to the 2-nitroimidazole family. Recently we have developed novel 2-nitroimidazole-derived PET radiotracer [18F]FBNA (N-(4-[18F]fluoro-benzyl)-2-(2-nitro-1H-imidazol-1-yl)-acet-amide), an 18F-labeled analogue of antiparasitic drug benznidazole. The present study aimed to analyze its radio-pharmacological properties and systematically compare its PET imaging profiles with [18F]FMISO and [18F]FAZA in preclinical triple-negative (MDA-MB231) and estrogen receptor-positive (MCF-7) breast cancer models.

METHODS

In vitro cellular uptake experiments were carried out in MDA-MB321 and MCF-7 cells under normoxic and hypoxic conditions. Metabolic stability in vivo was determined in BALB/c mice using radio-TLC analysis. Dynamic PET experiments over 3 h post-injection were performed in MDA-MB231 and MCF-7 tumour-bearing mice. Those PET data were used for kinetic modelling analysis utilizing the reversible two-tissue-compartment model. Autoradiography was carried out in tumour tissue slices and compared to HIF-1α immunohistochemistry. Detailed ex vivo biodistribution was accomplished in BALB/c mice, and this biodistribution data were used for dosimetry calculation.

RESULTS

Under hypoxic conditions in vitro cellular uptake was elevated in both cell lines, MCF-7 and MDA-MB231, for all three radiotracers. After intravenous injection, [18F]FBNA formed two radiometabolites, resulting in a final fraction of 65 ± 9 % intact [18F]FBNA after 60 min p.i. After 3 h p.i., [18F]FBNA tumour uptake reached SUV values of 0.78 ± 0.01 in MCF-7 and 0.61 ± 0.04 in MDA-MB231 tumours (both n = 3), representing tumour-to-muscle ratios of 2.19 ± 0.04 and 1.98 ± 0.15, respectively. [18F]FMISO resulted in higher tumour uptakes (SUV 1.36 ± 0.04 in MCF-7 and 1.23 ± 0.08 in MDA-MB231 (both n = 4; p < 0.05) than [18F]FAZA (0.66 ± 0.11 in MCF-7 and 0.63 ± 0.14 in MDA-MB231 (both n = 4; n.s.)), representing tumour-to-muscle ratios of 3.24 ± 0.30 and 3.32 ± 0.50 for [18F]FMISO, and 2.92 ± 0.74 and 3.00 ± 0.42 for [18F]FAZA, respectively. While the fraction per time of radiotracer entering the second compartment (k3) was similar within uncertainties for all three radiotracers in MDA-MB231 tumours, it was different in MCF-7 tumours. The ratios k3/(k3 + k2) and K1*k3/(k3 + k2) in MCF-7 tumours were also significantly different, indicating dissimilar fractions of radiotracer bound and trapped intracellularly: K1*k3/(k2 + k3) [18F]FMISO (0.0088 ± 0.001)/min, n = 4; p < 0.001) > [18F]FAZA (0.0052 ± 0.002)/min, n = 4; p < 0.01) > [18F]FBNA (0.003 ± 0.001)/min, n = 3). In contrast, in MDA-MB231 tumours, only K1 was significantly elevated for [18F]FMISO. However, this did not result in significant differences for K1*k3/(k2 + k3) for all three 2-nitroimidazoles in MDA-MB231 tumours.

CONCLUSION

Novel 2-nitroimidazole PET radiotracer [18F]FBNA showed uptake into hypoxic breast cancer cells and tumour tissue presumably associated with elevated HIF1-α expression. Systematic comparison of PET imaging performance with [18F]FMISO and [18F]FAZA in different types of preclinical breast cancer models revealed a similar tumour uptake profile for [18F]FBNA with [18F]FAZA and, despite its higher lipophilicity, still a slightly higher muscle tissue clearance compared to [18F]FMISO.

Enhanced Extraction of Blood and Tissue Time-Activity Curves in Cardiac Mouse FDG PET Imaging by Means of Constrained Nonnegative Matrix Factorization

We propose an enhanced method to accurately retrieve time-activity curves (TACs) of blood and tissue from dynamic 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) positron emission tomography (PET) cardiac images of mice. The method is noninvasive and consists of using a constrained nonnegative matrix factorization algorithm (CNMF) applied to the matrix (A) containing the intensity values of the voxels of the left ventricle (LV) PET image. CNMF factorizes A into nonnegative matrices H and W, respectively, representing the physiological factors (blood and tissue) and their associated weights, by minimizing an extended cost function. We verified our method on 32 C57BL/6 mice, 14 of them with acute myocardial infarction (AMI). With CNMF, we could break down the mouse LV into myocardial and blood pool images. Their corresponding TACs were used in kinetic modeling to readily determine the [¹⁸F]FDG influx constant (K_i) required to compute the myocardial metabolic rate of glucose. The calculated K_i values using CNMF for the heart of control mice were in good agreement with those published in the literature. Significant differences in K_i values for the heart of control and AMI mice were found using CNMF. The values of the elements of W agreed well with the LV structural changes induced by ligation of the left coronary artery. CNMF was compared with the recently published method based on robust unmixing of dynamic sequences using regions of interest (RUDUR). A clear improvement of signal separation was observed with CNMF compared to the RUDUR method.

Characterization of the partial volume effect along the axial field-of-view of the Biograph Vision Quadra total-body PET/CT system for multiple isotopes

BACKGROUND

Total-body PET scanners with axial field of views (FOVs) longer than 1 m enable new applications to study multiple organs (e.g., the brain-gut-axis) simultaneously. As the spatial resolution and the associated partial volume effect (PVE) can vary significantly along the FOV, detailed knowledge of the contrast recovery coefficients (CRCs) is a prerequisite for image analysis and interpretation of quantitative results. The aim of this study was to determine the CRCs, as well as voxel noise, for multiple isotopes throughout the 1.06 m axial FOV of the Biograph Vision Quadra PET/CT system (Siemens Healthineers).

MATERIALS AND METHODS

Cylindrical phantoms equipped with three different sphere sizes (inner diameters 7.86 mm, 28 and 37 mm) were utilized for the PVE evaluation. The 7.86 mm sphere was filled with F-18 (8:1 and 4:1), Ga-68 (8:1) and Zr-89 (8:1). The 28 mm and 37 mm spheres were filled with F-18 (8:1). Background concentration in the respective phantoms was of ~ 3 kBq/ml. The phantoms were measured at multiple positions in the FOV (axial: 0, 10, 20, 30, 40 and 50 cm, transaxial: 0, 10, 20 cm). The data were reconstructed with the standard clinical protocol, including PSF correction and TOF information with up to 10 iterations for maximum ring differences (MRDs) of 85 and 322; CRCs, as well as voxel noise levels, were determined for each position.

RESULTS

F-18 CRCs (SBR 8:1 and 4:1) of the 7.86 mm sphere decreased up to 18% from the center FOV (cFOV) toward the transaxial edge and increased up to 17% toward the axial edge. Noise levels were below 15% for the default clinical reconstruction parameters. The larger spheres exhibited a similar pattern. Zr-89 revealed ~ 10% lower CRCs than F-18 but larger noise (9.1% (F-18), 19.1% (Zr-89); iteration 4, cFOV) for the default reconstruction. Zr-89 noise levels in the cFOV significantly decreased (~ 28%) when reconstructing the data with MRD322 compared with MRD85 along with a slight decrease in CRC values. Ga-68 exhibited the lowest CRCs for the three isotopes and noise characteristics comparable to those of F-18.

CONCLUSIONS

Distinct differences in the PVE within the FOV were detected for clinically relevant isotopes F-18, Ga-68 and Zr-89, as well as for different sphere sizes. Depending on the positions inside the FOV, the sphere-to-background ratios, count statistics and isotope used, this can result in an up to 50% difference between CRCs. Hence, these changes in PVE can significantly affect the quantitative analysis of patient data. MRD322 resulted in slightly lower CRC values, especially in the center FOV, whereas the voxel noise significantly decreased compared with MRD85.

In Vitro and In Vivo Evaluation of ABCG2 (BCRP) Inhibitors Derived from Ko143

Breast cancer resistance protein (BCRP, ABCG2) is an efflux transporter that plays a crucial role in multidrug resistance to antineoplastic drugs. Ko143, an analogue of the natural product fumitremorgin C, is a potent inhibitor of ABCG2 but is rapidly hydrolyzed to an inactive metabolite in vivo. To identify ABCG2 inhibitors with improved metabolic stability, we have assessed a series of Ko143 analogues for their ability to inhibit ABCG2-mediated transport in ABCG2-transduced MDCK II cells and determined the stability of the most potent compounds in liver microsomes. The most promising analogues were evaluated in vivo by positron emission tomography. In vitro, three of the tested analogues were potent ABCG2 inhibitors and stable in microsomes. In vivo, they increased the distribution of the ABCG2/ABCB1 substrate [¹¹C]tariquidar to the brain both in wild-type (with Abcb1a/b transport blocked by tariquidar) and Abcb1a/b(-/-) mice. One analogue was more potent than Ko143 in both animal models.

Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice

BACKGROUND

Myocardial perfusion imaging by positron emission tomography (PET-MPI) is the current gold standard for quantification of myocardial blood flow. 18F-flurpiridaz was recently introduced as a valid alternative to currently used PET-MPI probes. Nonetheless, optimum scan duration and time interval for image analysis are currently unknown. Further, it is unclear whether rest/stress PET-MPI with 18F-flurpiridaz is feasible in mice.

METHODS

Rest/stress PET-MPI was performed with 18F-flurpiridaz (0.6-3.0 MBq) in 27 mice aged 7-8 months. Regadenoson (0.1 µg/g) was used for induction of vasodilator stress. Kinetic modeling was performed using a metabolite-corrected arterial input function. Image-derived myocardial 18F-flurpiridaz uptake was assessed for different time intervals by placing a volume of interest in the left ventricular myocardium.

RESULTS

Tracer kinetics were best described by a two-tissue compartment model. K1 ranged from 6.7 to 20.0 mL·cm-3·min-1, while myocardial volumes of distribution (VT) were between 34.6 and 83.6 mL·cm-3. Of note, myocardial 18F-flurpiridaz uptake (%ID/g) was significantly correlated with K1 at rest and following pharmacological vasodilation for all time intervals assessed. However, while Spearman's coefficients (rs) ranged between 0.478 and 0.681, R2 values were generally low. In contrast, an excellent correlation of myocardial 18F-flurpiridaz uptake with VT was obtained, particularly when employing the averaged myocardial uptake from 20 to 40 min post tracer injection (R2 ≥ 0.98). Notably, K1 and VT were similarly sensitive to pharmacological vasodilation induction. Further, mean stress-to-rest ratios of K1, VT, and %ID/g 18F-flurpiridaz were virtually identical, suggesting that %ID/g 18F-flurpiridaz can be used to estimate coronary flow reserve (CFR) in mice.

CONCLUSION

Our findings suggest that a simplified assessment of relative myocardial perfusion and CFR, based on image-derived tracer uptake, is feasible with 18F-flurpiridaz in mice, enabling high-throughput mechanistic CFR studies in rodents.

Error-prone protein synthesis recapitulates early symptoms of Alzheimer disease in aging mice

Age-related neurodegenerative diseases (NDDs) are associated with the aggregation and propagation of specific pathogenic protein species (e.g., Aβ, α-synuclein). However, whether disruption of synaptic homeostasis results from protein misfolding per se rather than accumulation of a specific rogue protein is an unexplored question. Here, we show that error-prone translation, with its frequent outcome of random protein misfolding, is sufficient to recapitulate many early features of NDDs, including perturbed Ca²⁺ signaling, neuronal hyperexcitability, and mitochondrial dysfunction. Mice expressing the ribosomal ambiguity mutation Rps9 D95N exhibited disrupted synaptic homeostasis resulting in behavioral changes reminiscent of early Alzheimer disease (AD), such as learning and memory deficits, maladaptive emotional responses, epileptiform discharges, suppressed circadian rhythmicity, and sleep fragmentation, accompanied by hippocampal NPY expression and cerebral glucose hypometabolism. Collectively, our findings suggest that random protein misfolding may contribute to the pathogenesis of age-related NDDs, providing an alternative framework for understanding the initiation of AD.

A companion to the preclinical common data elements and case report forms for in vivo rodent neuroimaging: A report of the TASK3-WG3 Neuroimaging Working Group of the ILAE/AES Joint Translational Task Force

The International League Against Epilepsy/American Epilepsy Society (ILAE/AES) Joint Translational Task Force established the TASK3 working groups to create common data elements (CDEs) for various aspects of preclinical epilepsy research studies, which could help improve the standardization of experimental designs. In this article, we discuss CDEs for neuroimaging data that are collected in rodent models of epilepsy, with a focus on adult rats and mice. We provide detailed CDE tables and case report forms (CRFs), and with this companion manuscript, we discuss the methodologies for several imaging modalities and the parameters that can be collected.

Performance Evaluation of a PET of 7T Bruker Micro-PET/MR Based on NEMA NU 4-2008 Standards

Purpose: This study aimed to measure the performance evaluation of the Bruker sequential micro-positron emission tomography/magnetic resonance imaging (PET/MRI) scanner by following National Electrical Manufacturers Association (NEMA) NU 4-2008 standards’ protocol. The system consists of a high-performance silicon photomultiplier (SiPM) advanced technology detector and a continuous lutetium-yttrium oxyorthosilicate (LYSO) crystal. Methods: A 22Na (sodium-22) point source was utilized to assess the spatial resolution and system sensitivity, and the Micro-PET scatter phantom measurements were conducted to measure count rate measurements and scatter fractions (SF). A mouse-like Micro-PET image quality (IQ) phantom was utilized as a model to analyze the uniformity, recovery coefficient (RC), and spillover ratio (SOR). A small animal PET/MRI imaging study was performed in a rat. Results: We calculated the spatial resolutions of filtered back-projection (FBP), and used 3D-MLEM to reconstruct PET images at the axial center and ¼ of the axial field of view (FOV) in axial, radial, and tangential directions. The best observed spatial resolutions in both reconstructed images were obtained in the tangential direction, and the values were 0.80 mm in 3D-MLEM and 0.94 mm in FBP. The peak noise equivalent count rate (NECR) in the 358–664 keV energy window was 477.30 kcps at 95.83 MBq and 774.45 kcps at 103.6 MBq for rat and mouse-sized scatter phantoms, respectively. The rat and mouse-sized phantoms scatter fractions (SF) were 14.2% and 6.9%, respectively. Conclusions: According to our results, the performance characteristics of the scanner are high sensitivity, good spatial resolution, low scatter fraction, and good IQ, indicating that it is suitable for preclinical imaging studies.

NEMA characterization of the SAFIR prototype PET insert

Background

The SAFIR prototype insert is a preclinical Positron Emission Tomography (PET) scanner built to acquire dynamic images simultaneously with a 7 T Bruker Magnetic Resonance Imaging (MRI) scanner. The insert is designed to perform with an excellent coincidence resolving time of 194 ps Full Width Half Maximum (FWHM) and an energy resolution of 13.8% FWHM. These properties enable it to acquire precise quantitative images at activities as high as 500 MBq suitable for studying fast biological processes within short time frames (< 5 s). In this study, the performance of the SAFIR prototype insert is evaluated according to the NEMA NU 4-2008 standard while the insert is inside the MRI without acquiring MRI data.

Results

Applying an energy window of 391–601 keV and a coincidence time window of 500 ps the following results are achieved. The average spatial resolution at 5 mm radial offset is 2.6 mm FWHM when using the Filtered Backprojection 3D Reprojection (FBP3DRP) reconstruction method, improving to 1.2 mm when using the Maximum Likelihood Expectation Maximization (MLEM) method. The peak sensitivity at the center of the scanner is 1.06%. The Noise Equivalent count Rate (NECR) is 799 kcps at the highest measured activity of 537 MBq for the mouse phantom and 121 kcps at the highest measured activity of 624 MBq for the rat phantom. The NECR peak is not yet reached for any of the measurements. The scatter fractions are 10.9% and 17.8% for the mouse and rat phantoms, respectively. The uniform region of the image quality phantom has a 3.0% STD, with a 4.6% deviation from the expected number of counts per voxel. The spill-over ratios for the water and air chambers are 0.18 and 0.17, respectively.

Conclusions

The results satisfy all the requirements initially considered for the insert, proving that the SAFIR prototype insert can obtain dynamic images of small rodents at high activities (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\sim$$\end{document}∼ 500 MBq) with a high sensitivity and an excellent count-rate performance.

PET Imaging of Estrogen Receptors Using 18F-Based Radioligands

In vivo molecular imaging of estrogen receptor alpha (ER) can be performed via positron emission tomography (PET) using ER-specific radioligands, such as 16α-[¹⁸F]fluoro-17β-estradiol (¹⁸F-FES). ¹⁸F-FES is a radiopharmaceutical recently approved by the United States Food and Drug Administration for use with PET imaging to detect ER+ lesions in patients with recurrent or metastatic breast cancer as an adjunct to biopsy. ¹⁸F-FES PET imaging has been used in clinical studies and preclinical research to assess whole-body ER protein expression and ligand binding function across multiple metastatic sites, to demonstrate inter-tumoral and temporal heterogeneity of ER expression, to quantify the pharmacodynamic effects of ER antagonist treatment, and to predict endocrine therapy response. ¹⁸F-FES PET has also been studied for imaging ER in endometrial and ovarian cancer. This chapter details the experimental protocol for ¹⁸F-FES PET imaging of ER in preclinical tumor xenograft models. Consistent adherence to key methodologic details will facilitate obtaining meaningful and reproducible ¹⁸F-FES PET preclinical imaging results, which could yield additional insight for clinical trials regarding imaging biomarkers and oncologic therapy.

Reconstruction of Preclinical PET Images via Chebyshev Polynomial Approximation of the Sinogram

Over the last decades, there has been an increasing interest in dedicated preclinical imaging modalities for research in biomedicine. Especially in the case of positron emission tomography (PET), reconstructed images provide useful information of the morphology and function of an internal organ. PET data, stored as sinograms, involve the Radon transform of the image under investigation. The analytical approach to PET image reconstruction incorporates the derivative of the Hilbert transform of the sinogram. In this direction, in the present work we present a novel numerical algorithm for the inversion of the Radon transform based on Chebyshev polynomials of the first kind. By employing these polynomials, the computation of the derivative of the Hilbert transform of the sinogram is significantly simplified. Extending the mathematical setting of previous research based on Chebyshev polynomials, we are able to efficiently apply our new Chebyshev inversion scheme for the case of analytic preclinical PET image reconstruction. We evaluated our reconstruction algorithm on projection data from a small-animal image quality (IQ) simulated phantom study, in accordance with the NEMA NU 4-2008 standards protocol. In particular, we quantified our reconstructions via the image quality metrics of percentage standard deviation, recovery coefficient, and spill-over ratio. The projection data employed were acquired for three different Poisson noise levels: 100% (NL1), 50% (NL2), and 20% (NL3) of the total counts, respectively. In the uniform region of the IQ phantom, Chebyshev reconstructions were consistently improved over filtered backprojection (FBP), in terms of percentage standard deviation (up to 29% lower, depending on the noise level). For all rods, we measured the contrast-to-noise-ratio, indicating an improvement of up to 68% depending on the noise level. In order to compare our reconstruction method with FBP, at equal noise levels, plots of recovery coefficient and spill-over ratio as functions of the percentage standard deviation were generated, after smoothing the NL3 reconstructions with three different Gaussian filters. When post-smoothing was applied, Chebyshev demonstrated recovery coefficient values up to 14% and 42% higher, for rods 1–3 mm and 4–5 mm, respectively, compared to FBP, depending on the smoothing sigma values. Our results indicate that our Chebyshev-based analytic reconstruction method may provide PET reconstructions that are comparable to FBP, thus yielding a good alternative to standard analytic preclinical PET reconstruction methods.

NEMA NU 4-2008 performance evaluation and MR compatibility tests of an APD-based small animal PET-insert for simultaneous PET/MR imaging

An avalanche photodiode (APD)-based small animal positron emission tomography (PET)-insert was fully evaluated for its PET performance, as well as potential influences on magnetic resonance imaging (MRI) performance. This PET-insert has an extended axial field of view (FOV) compared with the previous design to increase system sensitivity, as well as an updated cooling and temperature regulation to enable stable and reproducible PET acquisitions. The PET performance was evaluated according to the National Electrical Manufacturers Association NU4-2008 protocol. The energy and timing resolution’s full width at half maximum were 16.1% and 4.7 ns, respectively. The reconstructed radial spatial resolution of the PET-insert was 1.8 mm full width at half maximum at the center FOV using filtered back projection for reconstruction and sensitivity was 3.68%. The peak noise equivalent count rates were 70 kcps for a rat-like and 350 kcps for a mouse-like phantom, respectively. Image quality phantom values and contrast recovery were comparable to state-of-the art PET-inserts and standalone systems. Regarding MR compatibility, changes in the mean signal-to-noise ratio for turbo spin echo and echo-planar imaging sequences were below 8.6%, for gradient echo sequences below 1%. Degradation of the mean homogeneity was below 2.3% for all tested sequences. The influence of the PET-insert on the B 0 maps was negligible and no influence on functional MRI sequences was detected. A mouse and rat imaging study demonstrated the feasibility of in vivo simultaneous PET/MRI.

Performance evaluation of the IRIS XL-220 PET/CT system, a new camera dedicated to non-human primates

BACKGROUND

Non-human primates (NHP) are critical in biomedical research to better understand the pathophysiology of diseases and develop new therapies. Based on its translational and longitudinal abilities along with its non-invasiveness, PET/CT systems dedicated to non-human primates can play an important role for future discoveries in medical research. The aim of this study was to evaluate the performance of a new PET/CT system dedicated to NHP imaging, the IRIS XL-220 developed by Inviscan SAS. This was performed based on the National Electrical Manufacturers Association (NEMA) NU 4-2008 standard recommendations (NEMA) to characterize the spatial resolution, the scatter fraction, the sensitivity, the count rate, and the image quality of the system. Besides, the system was evaluated in real conditions with two NHP with ¹⁸F-FDG and (-)-[¹⁸F]FEOBV which targets the vesicular acetylcholine transporter, and one rat using ¹⁸F-FDG.

RESULTS

The full width at half maximum obtained with the 3D OSEM algorithm ranged between 0.89 and 2.11 mm in the field of view. Maximum sensitivity in the 400-620 keV and 250-750 keV energy windows were 2.37% (22 cps/kBq) and 2.81% (25 cps/kBq), respectively. The maximum noise equivalent count rate (NEC) for a rat phantom was 82 kcps at 75 MBq and 88 kcps at 75 MBq for energy window of 250-750 and 400-620 keV, respectively. For the monkey phantom, the maximum NEC was 18 kcps at 126 MBq and 19 kcps at 126 MBq for energy window of 250-750 and 400-620 keV, respectively. The IRIS XL provided an excellent quality of images in non-human primates and rats using ¹⁸F-FDG. The images acquired using (-)-[¹⁸F]FEOBV were consistent with those previously reported in non-human primates.

CONCLUSIONS

Taken together, these results showed that the IRIS XL-220 is a high-resolution system well suited for PET/CT imaging in non-human primates.

Physical and Imaging Performance of SIAT aPET under Different Energy Windows and Timing Windows

PURPOSE

The performance of small animal PET scanners depends on the energy window (EW) and timing window (TW). In NEMA Standards Publication NU 4-2008, detailed procedures of the performance measurements are defined, but the EW and TW are not specified. In this work, the effects of EW and TW on the physical and imaging performance of SIAT aPET will be evaluated.

METHODS

First, the flood histogram, energy resolution and timing resolution were measured for a detector of SIAT aPET. Second, the spatial resolutions were measured with different EWs. Third, the sensitivities, the scatter fractions (SFs), and noise equivalent count rates (NECRs) of a mouse-sized phantom and a rat-sized phantom, the recovery coefficients (RCs) of rods of different sizes, and the percentage standard deviation (%STD) of the NEMA image quality phantom were measured for different EWs and TWs. Last, images of a hot rod phantom, a mouse heart and a rat brain were acquired from the scanner with different EWs.

RESULTS

The SIAT aPET detectors provided good flood histograms such that all but the corner crystals can be resolved even with lower energies of 250-350 keV, an average energy resolution of 21.1±1.9 % and an average timing resolution of 2.63±0.69 ns. The average spatial resolutions obtained with EWs of 250-350 keV and 450-550 keV are 0.68 mm and 0.75 mm. For EWs of 250-750 keV, 350-750 keV, and 450-750 keV with a fixed TW of 12 ns, the sensitivities at center of field of view are 16.0%, 11.9%, and 8.2%, the peak NECRs of a mouse-sized phantom are 355.6 kcps, 324.4 kcps, and 249.4 kcps, and the peak NECRs of a rat-sized phantom are 148.5 kcps, 144.3 kcps, and 117.7 kcps, respectively. For the TWs of 4 ns, 8 ns,12 ns, and 20 ns with a fixed EW of 350-750 keV, the sensitivities at center of field of view are 9.6%, 11.4%, 11.9%, and 12.2%, the peak NECRs of a mouse-sized phantom are 260.1 kcps, 311.5 kcps, 324.4 kcps and 324.9 kcps, and the peak NECRs of a rat-sized phantom are 110.5 kcps, 137.3 kcps,144.3 kcps and 142.6 kcps, respectively. Narrowing the EW and TW improves the RCs of rods of all sizes, and the %STD of images obtained with different EWs and TWs are similar. Rods with diameter down to 0.8 mm can be visually resolved from images of the hot rod phantom obtained with different EWs. Images of mouse heart with high spatial resolution and rat brain with detail brain structure were obtained with different EWs. Images of both phantom and in-vivo animals obtained with different EWs only showed subtle difference.

CONCLUSION

The performance of SIAT aPET under different EWs and TWs was compared. The EW and TW affect the sensitivity, SF, and NECR, but not the spatial resolution and animal images of SIAT aPET, which imply that careful optimization of the EW and TW is not required. This article is protected by copyright. All rights reserved.

β-eye: A benchtop system for in vivo molecular screening of labeled compounds

Preclinical nuclear molecular imaging speeds up the mean time from synthesis to market, in drug development process. Commercial imaging systems have in general high cost, require high-cost service contracts, special facilities and trained staff. In the current work, we present β-eye, a benchtop system for in vivo molecular screening of labeled compounds with Positron Emission Tomography (PET) isotopes. The developed system is based on a dual-head geometry, offering simplicity and decreased cost. The goal of the design is to provide 2D, real-time radionuclide images of mice, allowing the recording of fast frames and thus perform fast kinetic studies, with spatial resolution of ∼2 mm. Performance evaluation demonstrates the ability of β-eye to provide quantitative results for injected activities lower than 1.5 MBq, which is adequate for pharmacodynamic studies in small mice.

Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine

The National Institutes of Health’s (National Cancer Institute) precision medicine initiative emphasizes the biological and molecular bases for cancer prevention and treatment. Importantly, it addresses the need for consistency in preclinical and clinical research. To overcome the translational gap in cancer treatment and prevention, the cancer research community has been transitioning toward using animal models that more fatefully recapitulate human tumor biology. There is a growing need to develop best practices in translational research, including imaging research, to better inform therapeutic choices and decision-making. Therefore, the National Cancer Institute has recently launched the Co-Clinical Imaging Research Resource Program (CIRP). Its overarching mission is to advance the practice of precision medicine by establishing consensus-based best practices for co-clinical imaging research by developing optimized state-of-the-art translational quantitative imaging methodologies to enable disease detection, risk stratification, and assessment/prediction of response to therapy. In this communication, we discuss our involvement in the CIRP, detailing key considerations including animal model selection, co-clinical study design, need for standardization of co-clinical instruments, and harmonization of preclinical and clinical quantitative imaging pipelines. An underlying emphasis in the program is to develop best practices toward reproducible, repeatable, and precise quantitative imaging biomarkers for use in translational cancer imaging and therapy. We will conclude with our thoughts on informatics needs to enable collaborative and open science research to advance precision medicine.

Technical Note: Performance evaluation of a small-animal PET/CT system based on NEMA NU 4-2008 standards

PURPOSE

The Metis^TM PET/CT is a self-developed, silicon photomultiplier (SiPM) detector-based, rodent PET/CT system. The objective of this study was to evaluate the performance of the system using the National Electrical Manufacturers Association (NEMA) NU 4-2008 standard protocol.

METHODS

Energy resolution, spatial resolution, sensitivity, scatter fraction (SF), noise-equivalent count rate (NECR), and image quality (IQ) characteristics were measured. A micro Derenzo phantom experiment was performed to evaluate the spatial resolution using three-dimensional ordered-subsets expectation maximization (3D-OSEM) and maximum likelihood expectation maximization (MLEM) reconstructed images. In addition, the CT imaging agent Ioverol 350 was mixed with fluorine-18 (¹⁸ F)-fluorodeoxyglucose (FDG) and then injected into the micro Derenzo phantom to evaluate the PET/CT imaging. In vivo PET/CT imaging studies were also conducted in a healthy mouse and rat using ¹⁸ F-FDG.

RESULTS

The mean energy resolution of the system was 15.3%. The tangential resolution was 0.82 mm full-width half-maximum (FWHM) at the center of the field of the view (FOV), and the radial and axial resolution were generally lower than 2.0 mm FWHM. The spatial resolution was significantly improved when using 3D-OSEM, especially the axial FWHM could be improved by up to about 57%. The system absolute sensitivity was 7.7% and 6.8% for an energy window of 200-750 and 350-750 keV respectively. The scatter fraction was 8.2% and 12.1% for the mouse- and rat-like phantom respectively. The peak NECR was 1343.72 kcps at 69 MBq and 640.32 kcps at 53 MBq for the mouse- and rat-like phantom respectively. The 1-mm fillable rod in the IQ phantom can be clearly observed. We can identify the 0.6-mm aperture of the micro Derenzo phantom image clearly using 3D-OSEM (10 subsets, 5 iterations). We also performed the fusion of the PET and CT images of the mouse and the brain imaging of the rat.

CONCLUSIONS

The results show that the system has the characteristics of high-resolution, high-sensitivity, and excellent IQ and is suitable for rodent imaging-based research.

Design study of a PET detector with 0.5 mm crystal pitch for high-resolution preclinical imaging

Preclinical positron emission tomography (PET) is a sensitive and quantitative molecule imaging modality widely used in characterizing the biological processes and diseases in small animals. The purpose of this study is to investigate the methods to optimize a PET detector for high-resolution preclinical imaging. The PET detector proposed in this study consists of a 28 × 28 array of LYSO crystals 0.5 × 0.5 × 6.25 mm³in size, a wedged lightguide, and a 6 × 6 array of SiPMs 3 × 3 mm²in size. The simulation results showed that the most uniform flood map was achieved when the thickness of the lightguide was 2.35 mm. The quality of the flood map was significantly improved by suppressing the electronics noises using the simple threshold method with a best threshold. The peak-to-valley ratio of flood map improved 25.4% when the algorithm of ICS rejection was applied. An energy resolution (12.96% ± 1.03%) was measured on the prototype scanner constructed with 12 proposed detectors. Lastly, a prototype preclinic PET imager was constructed with 12 optimized detectors. The point source experiment was performed and an excellent spatial resolution (axial: 0.56 mm, tangential: 0.46 mm, radial: 0.42 mm) was achieved with the proposed high-performance PET detectors.

Design and system evaluation of a dual-panel portable PET (DP-PET)

BACKGROUND

Integrated whole-body PET/MR technology continues to mature and is now extensively used in clinical settings. However, due to the special design architecture, integrated whole-body PET/MR comes with a few inherent limitations. Firstly, whole-body PET/MR lacks sensitivity and resolution for focused organs. Secondly, broader clinical access of integrated PET/MR has been significantly restricted due to its prohibitively high cost. The MR-compatible PET insert is an independent and removable PET scanner which can be placed within an MRI bore. However, the mobility and configurability of all existing MR-compatible PET insert prototypes remain limited.

METHODS

An MR-compatible portable PET insert prototype, dual-panel portable PET (DP-PET), has been developed for simultaneous PET/MR imaging. Using SiPM, digital readout electronics, novel carbon fiber shielding, phase-change cooling, and MRI compatible battery power, DP-PET was designed to achieve high-sensitivity and high-resolution with compatibility with a clinical 3-T MRI scanner. A GPU-based reconstruction method with resolution modeling (RM) has been developed for the DP-PET reconstruction. We evaluated the system performance on PET resolution, sensitivity, image quality, and the PET/MR interference.

RESULTS

The initial results reveal that the DP-PET prototype worked as expected in the MRI bore and caused minimal compromise to the MRI image quality. The PET performance was measured to show a spatial resolution ≤ 2.5 mm (parallel to the detector panels), maximum sensitivity = 3.6% at the center of FOV, and energy resolution = 12.43%. MR pulsing introduces less than 2% variation to the PET performance measurement results.

CONCLUSIONS

We developed a MR-compatible PET insert prototype and performed several studies to begin to characterize the performance of the proposed DP-PET. The results showed that the proposed DP-PET performed well in the MRI bore and would cause little influence on the MRI images. The Derenzo phantom test showed that the proposed reconstruction method could obtain high-quality images using DP-PET.

Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice

INTRODUCTION

The assessment of ex vivo biodistribution is the preferred method for quantification of radiotracers biodistribution in preclinical models, but is not in line with current ethics on animal research. PET imaging allows for noninvasive longitudinal evaluation of tracer distribution in the same animals, but systemic comparison with ex vivo biodistribution is lacking. Our aim was to evaluate the potential of preclinical PET imaging for accurate tracer quantification, especially in tumor models.

METHODS

NEMA NU 4-2008 phantoms were filled with ¹¹C, ⁶⁸Ga, ¹⁸F, or ⁸⁹Zr solutions and scanned in Mediso nanoPET/CT and PET/MR scanners until decay. N87 tumor-bearing mice were i.v. injected with either [¹⁸F]FDG (~ 14 MBq), kept 50 min under anesthesia followed by imaging for 20 min, or with [⁸⁹Zr]Zr-DFO-NCS-trastuzumab (~ 5 MBq) and imaged 3 days post-injection for 45 min. After PET acquisition, animals were killed and organs of interest were collected and measured in a γ-counter to determine tracer uptake levels. PET data were reconstructed using TeraTomo reconstruction algorithm with attenuation and scatter correction and regions of interest were drawn using Vivoquant software. PET imaging and ex vivo biodistribution were compared using Bland-Altman plots.

RESULTS

In phantoms, the highest recovery coefficient, thus the smallest partial volume effect, was obtained with ¹⁸F for both PET/CT and PET/MR. Recovery was slightly lower for ¹¹C and ⁸⁹Zr, while the lowest recovery was obtained with ⁶⁸Ga in both scanners. In vivo, tumor uptake of the ¹⁸F- or ⁸⁹Zr-labeled tracer proved to be similar irrespective whether quantified by either PET/CT and PET/MR or ex vivo biodistribution with average PET/ex vivo ratios of 0.8-0.9 and a deviation of 10% or less. Both methods appeared less congruent in the quantification of tracer uptake in healthy organs such as brain, kidney, and liver, and depended on the organ evaluated and the radionuclide used.

CONCLUSIONS

Our study suggests that PET quantification of ¹⁸F- and ⁸⁹Zr-labeled tracers is reliable for the evaluation of tumor uptake in preclinical models and a valuable alternative technique for ex vivo biodistribution. However, PET and ex vivo quantification require fully described experimental and analytical procedures for reliability and reproducibility.

Evaluation of the Small-animal Nano Scan PET/CT System using 89Zr

INTRODUCTION

The purpose of the present work was to evaluate the imaging characteristics of ⁸⁹Zr-PET in comparison with those obtained using fluorine-18 Fluorodeoxyglucose (18FFDG) PET (a gold standard tracer in PET imaging) using a small-animal NanoScan PET/CT scanner.

METHODS

The system's spatial resolution, sensitivity, uniformity, and image quality were measured on a Nano Scan small-animal PET/CT scanner according to the NEMA NU4-2008 protocols. For reconstruction images, we used 2D and 3D reconstruction algorithms. The reconstruction methods included filter back projection (FBP), the ordered subsets expectation maximization (OSEM) algorithm, and the 3D Tera-Tomo algorithm, which are developed for the NanoScan small-animal PET/CT scanner.

RESULTS

The results obtained showed a significant difference in the spatial resolution for ⁸⁹Zr as compared to 22Na and 18F when using a 2D reconstruction algorithm. The spatial resolution values were much enhanced by using the 3D Tera-Tomo reconstruction for each isotope, the Full width at half maximum (FWHM) values was less than 1 for all isotopes at the center of the field of view (FOV). This difference in spatial resolution is dependent on the positron range, energy, and the reconstruction method.

CONCLUSION

The long half-life of ⁸⁹Zr makes it an ideal positron emitter for performing immuno- PET, which is matched with the biological half-life of intact mAbs.⁸⁹Zr can also give several advantages over other long half-life positron emitters in relation to the overall imaging performance because of its relatively short positron range and simpler decay scheme. The values of ⁸⁹Zr sensitivity that were obtained in the present study were less than those of previous studies.

Quantitative Rodent Brain Receptor Imaging

Positron emission tomography (PET) is a non-invasive imaging technology employed to describe metabolic, physiological, and biochemical processes in vivo. These include receptor availability, metabolic changes, neurotransmitter release, and alterations of gene expression in the brain. Since the introduction of dedicated small-animal PET systems along with the development of many novel PET imaging probes, the number of PET studies using rats and mice in basic biomedical research tremendously increased over the last decade. This article reviews challenges and advances of quantitative rodent brain imaging to make the readers aware of its physical limitations, as well as to inspire them for its potential applications in preclinical research. In the first section, we briefly discuss the limitations of small-animal PET systems in terms of spatial resolution and sensitivity and point to possible improvements in detector development. In addition, different acquisition and post-processing methods used in rodent PET studies are summarized. We further discuss factors influencing the test-retest variability in small-animal PET studies, e.g., different receptor quantification methodologies which have been mainly translated from human to rodent receptor studies to determine the binding potential and changes of receptor availability and radioligand affinity. We further review different kinetic modeling approaches to obtain quantitative binding data in rodents and PET studies focusing on the quantification of endogenous neurotransmitter release using pharmacological interventions. While several studies have focused on the dopamine system due to the availability of several PET tracers which are sensitive to dopamine release, other neurotransmitter systems have become more and more into focus and are described in this review, as well. We further provide an overview of latest genome engineering technologies, including the CRISPR/Cas9 and DREADD systems that may advance our understanding of brain disorders and function and how imaging has been successfully applied to animal models of human brain disorders. Finally, we review the strengths and opportunities of simultaneous PET/magnetic resonance imaging systems to study drug-receptor interactions and challenges for the translation of PET results from bench to bedside.

Recommendations for Standardizing Thorax PET-CT in Non-Human Primates by Recent Experience from Macaque Studies

Despite the possibilities of routine clinical measures and assays on readily accessible bio-samples, it is not always essential in animals to investigate the dynamics of disease longitudinally. In this regard, minimally invasive imaging methods provide powerful tools in preclinical research. They can contribute to the ethical principle of gathering as much relevant information per animal as possible. Besides, with an obvious parallel to clinical diagnostic practice, such imaging platforms are potent and valuable instruments leading to a more refined use of animals from a welfare perspective. Non-human primates comprise highly relevant species for preclinical research to enhance our understanding of disease mechanisms and/or the development of improved prophylactic or therapeutic regimen for various human diseases. In this paper, we describe parameters that critically affect the quality of integrated positron emission tomography and computed tomography (PET-CT) in non-human primates. Lessons learned are exemplified by results from imaging experimental infectious respiratory disease in macaques; specifically tuberculosis, influenza, and SARS-CoV-2 infection. We focus on the thorax and use of 18F-fluorodeoxyglucose as a PET tracer. Recommendations are provided to guide various stages of PET-CT-supported research in non-human primates, from animal selection, scan preparation, and operation, to processing and analysis of imaging data.

Preclinical techniques to investigate exercise training in vascular pathophysiology

Atherosclerosis is a dynamic process starting with endothelial dysfunction and inflammation and eventually leading to life-threatening arterial plaques. Exercise generally improves endothelial function in a dose-dependent manner by altering hemodynamics, specifically by increased arterial pressure, pulsatility, and shear stress. However, athletes who regularly participate in high-intensity training can develop arterial plaques, suggesting alternative mechanisms through which excessive exercise promotes vascular disease. Understanding the mechanisms that drive atherosclerosis in sedentary versus exercise states may lead to novel rehabilitative methods aimed at improving exercise compliance and physical activity. Preclinical tools, including in vitro cell assays, in vivo animal models, and in silico computational methods, broaden our capabilities to study the mechanisms through which exercise impacts atherogenesis, from molecular maladaptation to vascular remodeling. Here, we describe how preclinical research tools have and can be used to study exercise effects on atherosclerosis. We then propose how advanced bioengineering techniques can be used to address gaps in our current understanding of vascular pathophysiology, including integrating in vitro, in vivo, and in silico studies across multiple tissue systems and size scales. Improving our understanding of the antiatherogenic exercise effects will enable engaging, targeted, and individualized exercise recommendations to promote cardiovascular health rather than treating cardiovascular disease that results from a sedentary lifestyle.

Evaluation of image quality with four positron emitters and three preclinical PET/CT systems

Background

We investigated the image quality of ¹¹C, ⁶⁸Ga, ¹⁸F and ⁸⁹Zr, which have different positron fractions, physical half-lifes and positron ranges. Three small animal positron emission tomography/computed tomography (PET/CT) systems were used in the evaluation, including the Siemens Inveon, RAYCAN X5 and Molecubes β-cube. The evaluation was performed on a single scanner level using the national electrical manufacturers association (NEMA) image quality phantom and analysis protocol. Acquisitions were performed with the standard NEMA protocol for ¹⁸F and using a radionuclide-specific acquisition time for ¹¹C, ⁶⁸Ga and ⁸⁹Zr. Images were assessed using percent recovery coefficient (%RC), percentage standard deviation (%STD), image uniformity (%SD), spill-over ratio (SOR) and evaluation of image quantification.

Results

⁶⁸Ga had the lowest %RC (< 62%) across all systems. ¹⁸F had the highest maximum %RC (> 85%) and lowest %STD for the 5 mm rod across all systems. For ¹¹C and ⁸⁹Zr, the maximum %RC was close (> 76%) to the %RC with ¹⁸F. A larger SOR were measured in water with ¹¹C and ⁶⁸Ga compared to ¹⁸F on all systems. SOR in air reflected image reconstruction and data correction performance. Large variation in image quantification was observed, with maximal errors of 22.73% (⁸⁹Zr, Inveon), 17.54% (⁸⁹Zr, RAYCAN) and − 14.87% (⁶⁸Ga, Molecubes).

Conclusions

The systems performed most optimal in terms of NEMA image quality parameters when using ¹⁸F, where ¹¹C and ⁸⁹Zr performed slightly worse than ¹⁸F. The performance was least optimal when using ⁶⁸Ga, due to large positron range. The large quantification differences prompt optimization not only by terms of image quality but also quantification. Further investigation should be performed to find an appropriate calibration and harmonization protocol and the evaluation should be conducted on a multi-scanner and multi-center level.

Design and performance of SIAT aPET: a uniform high-resolution small animal PET scanner using dual-ended readout detectors

In this work, a small animal PET scanner named SIAT aPET was developed using dual-ended readout depth encoding detectors to simultaneously achieve high spatial resolution and high sensitivity. The scanner consists of four detector rings with 12 detector modules per ring; the ring diameter is 111 mm and the axial field of view (FOV) is 105.6 mm. The images are reconstructed using an ordered subset expectation maximization (OSEM) algorithm. The spatial resolution of the scanner was measured by using a ²²Na point source at the center axial FOV with different radial offsets. The sensitivity of the scanner was measured at center axis of the scanner with different axial positions. The count rate performance of the system was evaluated by scanning mouse-sized and rat-sized phantoms. An ultra-micro hot-rods phantom and two mice injected with ¹⁸F-NaF and ¹⁸F-FDG were scanned on the scanner. An average depth of interaction (DOI) resolution of 1.96 mm, energy resolution of 19.1% and timing resolution of 1.20 ns were obtained for the detector. Average spatial resolutions of 0.82 mm and 1.16 mm were obtained up to a distance of 30 mm radially from the center of the FOV when reconstructing a point source in 1% and 10% warm backgrounds, respectively, using OSEM reconstruction with 16 subsets and 10 iterations. Sensitivities of 16.0% and 11.9% were achieved at center of the scanner for energy windows of 250-750 keV and 350-750 keV respectively. Peak noise equivalent count rates (NECRs) of 324 kcps and 144 kcps were obtained at an activity of 26.4 MBq for the mouse-sized and rat-sized phantoms. Rods of 1.0 mm diameter can be visually resolved from the image of the ultra-micro hot-rods phantom. The capability of the scanner was demonstrated by high quality in-vivo mouse images.

Performance evaluation of fifth-generation ultra-high-resolution SPECT system with two stationary detectors and multi-pinhole imaging

Background

Small-animal single-photon emission computed tomography (SPECT) systems with multi-pinhole collimation and large stationary detectors have advantages compared to systems with moving small detectors. These systems benefit from less labour-intensive maintenance and quality control as fewer prone parts are moving, higher accuracy for focused scans and maintaining high resolution with increased sensitivity due to focused pinholes on the field of view. This study aims to investigate the performance of a novel ultra-high-resolution scanner with two-detector configuration (U-SPECT5-E) and to compare its image quality to a conventional micro-SPECT system with three stationary detectors (U-SPECT⁺).

Methods

The new U-SPECT5-E with two stationary detectors was used for acquiring data with ^99mTc-filled point source, hot-rod and uniformity phantoms to analyse sensitivity, spatial resolution, uniformity and contrast-to-noise ratio (CNR). Three dedicated multi-pinhole mouse collimators with 75 pinholes each and 0.25-, 0.60- and 1.00-mm pinholes for extra ultra-high resolution (XUHR-M), general-purpose (GP-M) and ultra-high sensitivity (UHS-M) imaging were examined. For CNR analysis, four different activity ranges representing low- and high-count settings were investigated for all three collimators. The experiments for the performance assessment were repeated with the same GP-M collimator in the three-detector U-SPECT⁺ for comparison.

Results

Peak sensitivity was 237 cps/MBq (XUHR-M), 847 cps/MBq (GP-M), 2054 cps/MBq (UHS-M) for U-SPECT5-E and 1710 cps/MBq (GP-M) for U-SPECT⁺. In the visually analysed sections of the reconstructed mini Derenzo phantoms, rods as small as 0.35 mm (XUHR-M), 0.50 mm (GP-M) for the two-detector as well as the three-detector SPECT and 0.75 mm (UHS-M) were resolved. Uniformity for maximum resolution recorded 40.7% (XUHR-M), 29.1% (GP-M, U-SPECT5-E), 16.3% (GP-M, U-SPECT⁺) and 23.0% (UHS-M), respectively. UHS-M reached highest CNR values for low-count images; for rods smaller than 0.45 mm, acceptable CNR was only achieved by XUHR-M. GP-M was superior for imaging rods sized from 0.60 to 1.50 mm for intermediate activity concentrations. U-SPECT5-E and U-SPECT⁺ both provided comparable CNR.

Conclusions

While uniformity and sensitivity are negatively affected by the absence of a third detector, the investigated U-SPECT5-E system with two stationary detectors delivers excellent spatial resolution and CNR comparable to the performance of an established three-detector-setup.

[11C]mHED PET follows a two-tissue compartment model in mouse myocardium with norepinephrine transporter (NET)-dependent uptake, while [18F]LMI1195 uptake is NET-independent

PURPOSE

Clinical positron emission tomography (PET) imaging of the presynaptic norepinephrine transporter (NET) function provides valuable diagnostic information on sympathetic outflow and neuronal status. As data on the NET-targeting PET tracers [¹¹C]meta-hydroxyephedrine ([¹¹C]mHED) and [¹⁸F]LMI1195 ([¹⁸F]flubrobenguane) in murine experimental models are scarce or lacking, we performed a detailed characterization of their myocardial uptake pattern and investigated [¹¹C]mHED uptake by kinetic modelling.

METHODS

[¹¹C]mHED and [¹⁸F]LMI1195 accumulation in the heart was studied by PET/CT in FVB/N mice. To test for specific uptake by NET, desipramine, a selective NET inhibitor, was administered by intraperitoneal injection. [¹¹C]mHED kinetic modelling with input function from an arteriovenous shunt was performed in three mice.

RESULTS

Both tracers accumulated in the mouse myocardium; however, only [¹¹C]mHED uptake was significantly reduced by excess amount of desipramine. Myocardial [¹¹C]mHED uptake was half-saturated at 88.3 nmol/kg of combined mHED and metaraminol residual. After [¹¹C]mHED injection, a radiometabolite was detected in plasma and urine, but not in the myocardium. [¹¹C]mHED kinetics followed serial two-tissue compartment models with desipramine-sensitive K₁.

CONCLUSION

PET with [¹¹C]mHED but not [¹⁸F]LMI1195 provides information on NET function in the mouse heart. [¹¹C]mHED PET is dose-independent in the mouse myocardium at < 10 nmol/kg of combined mHED and metaraminol. [¹¹C]mHED kinetics followed serial two-tissue compartment models with K₁ representing NET transport. Myocardial [¹¹C]mHED uptake obtained from PET images may be used to assess cardiac sympathetic integrity in mouse models of cardiovascular disease.

In Vivo Imaging of Local Inflammation: Monitoring LPS-Induced CD80/CD86 Upregulation by PET

Purpose

The co-stimulatory molecules CD80 and CD86 are upregulated on activated antigen-presenting cells (APC). We investigated whether local APC activation, induced by subcutaneous (s.c.) inoculation of lipopolysaccharides (LPS), can be imaged by positron emission tomography (PET) with CD80/CD86-targeting ⁶⁴Cu-labelled abatacept.

Procedures

Mice were inoculated s.c. with extracellular-matrix gel containing either LPS or vehicle (PBS). Immune cell populations were analysed by flow cytometry and marker expression by RT-qPCR. ⁶⁴Cu-NODAGA-abatacept distribution was analysed using PET/CT and ex vivo biodistribution.

Results

The number of CD80⁺ and CD86⁺ immune cells at the LPS inoculation site significantly increased a few days after inoculation. CD68 and CD86 expression were higher at the LPS than the PBS inoculation site, and CD80 was only increased at the LPS inoculation site. CTLA-4 was highest 10 days after LPS inoculation, when CD80/CD86 decreased again. A few days after inoculation, ⁶⁴Cu-NODAGA-abatacept distribution to the inoculation site was significantly higher for LPS than PBS (4.2-fold). Co-administration of unlabelled abatacept or human immunoglobulin reduced tracer uptake. The latter reduced the number of CD86⁺ immune cells at the LPS inoculation site.

Conclusions

CD80 and CD86 are upregulated in an LPS-induced local inflammation, indicating invasion of activated APCs. ⁶⁴Cu-NODAGA-abatacept PET allowed following APC activation over time.

Electronic supplementary material

The online version of this article (10.1007/s11307-020-01543-3) contains supplementary material, which is available to authorized users.

Advances in Preclinical PET Instrumentation

In the light of ever-increasing demands for PET scanner with better resolvability, higher sensitivity and wide accessibility for noninvasive screening of small structures and physiological processes in laboratory rodents, several dedicated PET scanners were developed and evaluated. Understanding conceptual design constraints pros and cons of different configurations and impact of the major components will be helpful to further establish the crucial role of these miniaturized systems in a broad spectrum of modern research. Hence, a comprehensive review of preclinical PET scanners developed till early 2020 with particular emphasis on innovations in instrumentation and geometrical designs is provided.

Digital autoradiography for efficient functional imaging without anesthesia in experimental animals: Reversing phencyclidine-induced functional alterations using clozapine

Autoradiography (ARG) is a high-resolution imaging method for localization of radiolabeled biomarkers in ex vivo specimen. ARG using 2-deoxy-d-glucose (2-DG) method is used in to study drug actions on brain functional activity, as it provides results comparable to clinically used functional positron-emission tomography (PET). The requirement of slow analog detection methods and emerging advances in small animal PET imaging have, however, reduced the interest in ARG. In contrast to ARG, experimental animals need to be restrained or sedated/anesthetized for PET imaging, which strongly influence functional activity and thus complicate the interpretation of the results. Digital direct particle-counting ARG systems have gained attraction during the last decade to overcome the caveats of conventional ARG methods. Here we demonstrate that the well-established 2-DG imaging method can be adapted into use with contemporary digital detectors. This method readily and rapidly captures the characteristic effects of phencyclidine (5 mg/kg, i.p.), a dissociative agent targeting the NMDAR (N-methyl-d-aspartate receptor), on regional glucose utilization in the adult mouse brain. Pretreatment with antipsychotic drug clozapine (6 mg/kg, i.p.) essentially abolishes these effects of phencyclidine on brain functional activity. Digital ARG produces viable data for the regional analysis of functional activity in a fraction of time required for film development. These results support the use of digital ARG in preclinical drug research, where high throughput and response linearity are preferred and use of sedation/anesthesia has to be avoided.

Small animal PET: a review of what we have done and where we are going

Small animal research is an essential tool in studying both pharmaceutical biodistributions and disease progression over time. Furthermore, through the rapid development of in vivo imaging technology over the last few decades, small animal imaging (also referred to as preclinical imaging) has become a mainstay for all fields of biologic research and a center point for most preclinical cancer research. Preclinical imaging modalities include optical, MRI and MRS, microCT, small animal PET, ultrasound, and photoacoustic, each with their individual strengths. The strong points of small animal PET are its translatability to the clinic; its quantitative imaging capabilities; its whole-body imaging ability to dynamically trace functional/biochemical processes; its ability to provide useful images with only nano- to pico‑ molar concentrations of administered compounds; and its ability to study animals serially over time. This review paper gives an overview of the development and evolution of small animal PET imaging. It provides an overview of detector designs; system configurations; multimodality PET imaging systems; image reconstruction and analysis tools; and an overview of research and commercially available small animal PET systems. It concludes with a look toward developing technologies/methodologies that will further enhance the impact of small animal PET imaging on medical research in the future.

Real-Time 3D PET Image with Pseudoinverse Reconstruction

Real-time positron emission tomography (PET) may provide information from first-shot images, enable PET-guided biopsies, and allow awake animal studies. Fully-3D iterative reconstructions yield the best images in PET, but they are too slow for real-time imaging. Analytical methods such as Fourier back projection (FBP) are very fast, but yield images of poor quality with artifacts due to noise or data incompleteness. In this work, an image reconstruction based on the pseudoinverse of the system response matrix (SRM) is presented. w. To implement the pseudoinverse method, the reconstruction problem is separated into two stages. First, the axial part of the SRM is pseudo-inverted (PINV) to rebin the 3D data into 2D datasets. Then, the resulting 2D slices can be reconstructed with analytical methods or by applying the pseudoinverse algorithm again. The proposed two-step PINV reconstruction yielded good-quality images at a rate of several frames per second, compatible with real time applications. Furthermore, extremely fast direct PINV reconstruction of projections of the 3D image collapsed along specific directions can be implemented.

Real-Time 3D PET Image with Pseudoinverse Reconstruction

Real-time positron emission tomography (PET) may provide information from first-shot images, enable PET-guided biopsies, and allow awake animal studies. Fully-3D iterative reconstructions yield the best images in PET, but they are too slow for real-time imaging. Analytical methods such as Fourier back projection (FBP) are very fast, but yield images of poor quality with artifacts due to noise or data incompleteness. In this work, an image reconstruction based on the pseudoinverse of the system response matrix (SRM) is presented. w. To implement the pseudoinverse method, the reconstruction problem is separated into two stages. First, the axial part of the SRM is pseudo-inverted (PINV) to rebin the 3D data into 2D datasets. Then, the resulting 2D slices can be reconstructed with analytical methods or by applying the pseudoinverse algorithm again. The proposed two-step PINV reconstruction yielded good-quality images at a rate of several frames per second, compatible with real time applications. Furthermore, extremely fast direct PINV reconstruction of projections of the 3D image collapsed along specific directions can be implemented.

Guidelines for the experimental design of pharmacokinetic studies with nanomaterials in preclinical animal models

A shared feature in the value proposition of every nanomaterial-based drug delivery systems is the desirable improvement in the disposition (or ADME) and pharmacokinetic profiles of the encapsulated drug being delivered. Remarkable progress has been made towards understanding the complex and multifactorial relationships between pharmacokinetic profiles and nanomaterial physicochemical properties, biological interactions, species physiology, etc. These advances have fuelled the rational design of numerous nanomaterials with long-circulation times and improved tissue accumulation (e.g., in tumours). Unfortunately, a central weakness in many of these research efforts has been the inconsistent and insufficient characterisation of the pharmacokinetic profiles of nanomaterials in scientific reporting-a problem affecting the majoirty of of contemporary nanomaterials literature and innovative nanomaterials in early stages of preclinical development especially. Given the significant role of pharmacokinetic assessments to serve as guideposts for deciding whether to continue with the preclinical development and clinical translation of drug delivery systems, the prevalence of poor pharmacokinetic characterisations in nanomaterials research is particularly alarming. A conspicuous problem in many reports is the inappropriate selection of experimental designs and methodologies for studying nanomaterial pharmacokinetics, the consequences of which are increased uncertainty over the accurate interpretation of reported pharmacokinetic data and diminished experimental reproducibility throughout the field. Thus, there is renewed interest in the establishment of consistent and comprehensive strategies for designing preclinical experiments to assess the pharmacokinetics of nanomaterials with diverse physicochemical properties. Towards this end, herein are proposed simple guidelines for the experimental design of pharmacokinetic studies with nanomaterials drawn from the best research practices, principle strategies, and important considerations used in industry for collecting pharmacokinetic data in preclinical animal models. Specifically, key experimental design factors in these studies are identified and examined in the context of nanomaterials for optimality, including blood sampling strategy and technique, sample allocation and sampling time window, test species selection, experimental sources of pharmacokinetic variability, etc. Methods for noninvasive imaging-derived pharmacokinetic assessments of theranostic nanomaterials are also explored with particular focus on emission tomography imaging modalities. Taken together, this review will provide nanomaterial researchers with practical knowledge and pragmatic recommendations for selecting the best designs and methodologies for assessing the pharmacokinetic profiles of their nanomaterials, and hopefully maximise the chances of translational success of these innovative products into humans.

Cerenkov luminescence and PET imaging of 90Y: capabilities and limitations in small animal applications

The in vivo sensitivity limits and quantification performance of Cerenkov luminescence imaging have been studied using a tissue-like mouse phantom and ⁹⁰Y. For a small, 9 mm deep target in the phantom, with no background activity present, the Cerenkov luminescence ⁹⁰Y detection limit determined from contrast-to-noise ratios is 10 nCi for a 2 min exposure with a sensitive CCD camera and no filters. For quantitative performance, the values extracted from regions of interest on the images are linear within 5% of a straight line fit versus target activity for target activity of 70 nCi and above. The small branching ratio to decay with positron emission for ⁹⁰Y also permits low-statistics PET imaging of the radionuclide. For PET imaging of the same phantom, with a small animal LSO detector-based scanner, the ⁹⁰Y detection limit is approximately 3 orders of magnitude higher at 10 µCi.